Study explores novel combo of pidnarulex and talazoparib in mCRPC
Researchers hope to find synergistic effects with the combination of the ribosomal RNA synthesis inhibitor pidnarulex and the PARP inhibitor talazoparib.
Pidnarulex could be a future option for patients with BRCA 1/2-positive mCRPC who are resistant to treatment with FDA-approved PARP inhibitors.
The first patient has been dosed in the phase 1 REPAIR trial (NCT05425862) exploring the investigational combination of pidnarulex (CX-5461) and talazoparib (Talzenna) in patients with metastatic castration-resistant prostate cancer (mCRPC).1
Pidnarulex is an agent that targets the DNA repair irregularities in tumors with homologous recombination deficiency. The agent works by stabilizing DNA G-quadruplexes of cancer cells and interfering with the cell’s replication fork. Conclusively, pidnarulex leads to cancer cell death.
The FDA recently granted fast track designation to pidnarulex for the treatment patients with BRCA 1/2- and PALB2-positive ovarian or breast cancers. Considering that prevalence of BRCA 1/2-positive prostate cancer tumors, pidnarulex may have a role in the United States. Specifically, the agent could be a future option for patients with BRCA 1/2-positive mCRPC who are resistant to treatment with FDA-approved PARP inhibitors.
REPAIR has an open-label, multicenter, dose-escalation design. The targeted enrollment goal is 48 patients and the estimated primary completion date is July 12, 2024.2
During the study, patients with mCRPC will be given escalated doses of both pidnarulex and talazoparib to achieve the primary end point of determining the maximum-tolerated dose of pidnarulex, as well as the recommended phase 2 dose. Secondary end points that will be assessed during the study include safety, prostate specific antigen (PSA) response, radiographic progression-free survival (PFS), PSA PFS, overall survival, duration of response, and treatment discontinuation rate.2
Patients are eligible to enroll in REPAIR if they are 18 years of age or older with histologically or cytologically confirmed mCRPC, an ECOG performance status of at least 1, and adequate bone marrow, hepatic, and renal function. Further, patients must have a PSA of ≥ 5ng/ml at the time of registration, as well as serum testosterone levels ≤ 50ng/dL within 28 days prior to cycle 1 day 1, and a life expectancy of at least 24 weeks.
Patients are also required to have progressed on a second-generation androgen receptor targeted therapy, received at least 1 prior line of chemotherapy, have progressive disease at the time of study entry, or have undergone prior surgical orchiectomy or chemical castration.
The study is actively recruiting patients for the first study site, Peter MacCallum Cancer Centre in Melbourne, Australia.
“Pidnarulex alone has shown efficacy in tumor cells resistant to PARPi in the preclinical studies. Therefore, we think pidnarulex demonstrates great potential as an alternative treatment for prostate cancer patients who have acquired resistance to PARPi or other chemotherapies,” Jin-Ding Huang, PhD, chief executive officer, Senhwa Biosciences, the developer of pidnarulex, stated in a press release.1
References
1. Senhwa announces first patient successfully dosed in phase i study of pindnarulex in combination with Pfizer’s talazoparib for the treatment of prostate cancer. News release. October 31, 2022. Accessed November 1, 2022. https://www.senhwabio.com/en/news/20221031
2. Pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer (REPAIR). ClinicalTrials.gov. Updates October 28, 2022. Accessed November 1, 2022. https://clinicaltrials.gov/ct2/show/NCT05425862?term=CX-5461&draw=2&rank=3
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
